Journal
AIDS
Volume 26, Issue 13, Pages 1721-1724Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0b013e3283568884
Keywords
-
Categories
Funding
- Ministerio de Sanidad [ISCIII-RETIC RD06/006]
- Fundacion para la Investigacion y la Prevencion del Sida en Espana [360799/09]
- research extension grant from the Fundacion Progreso y Salud, Consejeria de Salud de la Junta de Andalucia [AI-0011-2010]
- intensification grant from the Instituto de Salud Carlos III [Programa-I3SNS]
- GlaxoSmithMine
- Bristol-Myers Squibb
- Abbott Pharmaceuticals
- Gilead
- Merck Sharp Dohme
- Schering-Plough
- Janssen-Cilag
- Boehringer Ingelheim
- Roche
Ask authors/readers for more resources
We assess the efficacy of pegylated interferon (peg-IFN) with ribavirin (RBV) and the predictors of sustained virological response (SVR) among HIV/hepatitis C virus genotype 4 (HCV-4)-coinfected patients. Thirty-nine (31.5%) of 124 individuals with HCV-4 achieved SVR compared with 103 (22.7%) of 453 individuals with HCV genotype 1 (P=0.046). Only interleukin-28B (IL28B) genotype CC was independently associated with SVR in HIV/HCV-4-coinfected patients. The efficacy of peg-IFN with RBV in coinfected individuals with genotype 4 is significantly higher than in those with genotype 1. IL28B CC genotype is the main predictor of response in this population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available